For years, Ozempic and similar GLP-1 medications have dominated the weight loss conversationbut a new game changer drug from Eli Lilly may soon shift the landscape
Heat shock protein gene expression profile may differentiate between rheumatoid arthritis, osteoarthritis, and healthy controls
Zepbound's starting dose (2.5 mg) produces measurable weight loss in most patients
Found uses a mostly virtual process built to make GLP-1 treatment safer and simpler
Generalised pruritus and urticaria are uncommon, potentially indicating hypersensitivity reactions
Clinics seeing the strongest outcomes rely on standardized clinical protocols, structured documentation, and consistent outcome tracking to support individualized dosing, biomarker monitoring, and patient safety